A prominent psychiatry researcher is dismissed. What’s happening to his papers?

neumeister
Alexander Neumeister. Source: Yale School of Medicine

After a prominent researcher was dismissed due to multiple instances of misconduct in his studies, how are journals responding?

When an investigation by the U.S. Food and Drug Administration (FDA) found multiple issues with the work of psychiatry researcher Alexander Neumeister, New York University (NYU) Langone Medical Center shut down eight of his studies. (Disclosure: The author of this post is an NYU journalism student, but has no relationship with the medical school.) The agency concluded the studies, which involved using experimental drugs to relieve symptoms of post-traumatic stress disorder (PTSD), were tainted by lax oversight, falsified records, and inaccurate case histories, according to the New York Times. (Neuroskeptic also recently analyzed the case.)

We reached out to the journals that have published Neumeister’s papers, to ask if these recent events have caused them to take a second look at his work. Several have responded, with some noting they plan to investigate, or will do so if asked by the institution. But many believe there is little cause for concern. Continue reading A prominent psychiatry researcher is dismissed. What’s happening to his papers?

Should a paper be retracted if an author omits a conflict of interest?

s-cover-yvs1606A JAMA journal has quickly issued a correction for a 2016 paper after the author failed to mention several relevant conflicts of interest. Normally, we’d see this as a run-of-the-mill correction notice, but since we reported last week that a journal retracted a paper for omitting pharma funding, we got to wondering: Is failure to disclose a conflict of interest a retractable offense?

Guidelines from the Committee on Publication Ethics (COPE) do say that retractions are used for “failure to disclose a major competing interest likely to influence interpretations or recommendations.” But most of the time when we see corrections to the literature for such omissions, they’re corrections, not retractions.

On Friday, JAMA Ophthalmology issued a correction notice for an invited commentary published in April, which addressed two papers in the journal about melanoma of the eye (uveal melanoma). However, the original commentary failed to note that author Arun D. Singh at the Cleveland Clinic had some relevant conflicts to mention, as the notice explains: Continue reading Should a paper be retracted if an author omits a conflict of interest?

Five more retractions for biologist with funding ban brings total to six

Journal of Cell ScienceAn erstwhile cell biologist has retracted five papers published in the Journal of Cell Science (JCS), all of which had been flagged in a recent investigation by the U.S. Office of Research Integrity (ORI).

The investigation found John Pastorino, previously a cell biologist at Rowan University in New Jersey, guilty of doctoring more than 40 images, resulting in a five-year funding ban.

The probe identified eight papers co-authored by Pastorino, six of which had already received expressions of concern (EOC) — including all of the newly retracted JCS papers. Nataly Shulga is a co-author on all eight papers.

Last week, we reported on the first of the expected retractions of the flagged papers in the Journal of Biological Chemistry.

Here are the retraction notices, which are the same for all five JCS papers: Continue reading Five more retractions for biologist with funding ban brings total to six

Crow’s feet filler study omitted pharma funding, gets retracted

JKMSA paper on a filler for eye wrinkles did not disclose that it was funded by a pharmaceutical company that produces the cosmetic.

The paper explicitly noted that the authors do not have any financial conflicts of interest, and that a government program supported the study. According to the journal, a reader alerted them to the conflict of interest.

The cooperate tie wasn’t a secret, though — one of the authors was listed as affiliated with the  company, Pharma Research Products, based in Korea.

Here’s the retraction notice for “A Phase III, Randomized, Double-Blind, Matched-Pairs, Active-Controlled Clinical Trial and Preclinical Animal Study to Compare the Durability, Efficacy and Safety between Polynucleotide Filler and Hyaluronic Acid Filler in the Correction of Crow’s Feet: A New Concept of Regenerative Filler:”

Continue reading Crow’s feet filler study omitted pharma funding, gets retracted

You’ve been dupe’d (again): Do these data look familiar? They are

plant_growth_regulationWe can’t keep up with the growing number of retraction notices, so we’ve compiled a list of recent duplications to update our records.

1. Authors don’t always intentionally duplicate their own work, of course. The first paper on our list was retracted after the authors included a figure from a previous paper by accident, according to the publisher: Continue reading You’ve been dupe’d (again): Do these data look familiar? They are

Diabetes researcher logged 1 retraction, 3 correx, after PubPeer comments

Kathrin Maelder
Kathrin Maedler

A journal has retracted a paper by a leading diabetes researcher — who has also issued three corrections — after questions about her research were raised on PubPeer.

Kathrin Maedler — who works at the University of Bremen in Germany — corrected another paper in 2014. All of the notices are dated from 2015, and all describe issues with figures.

The ongoing comments have led Maedler to carefully look through her original data, according to a statement she emailed us: Continue reading Diabetes researcher logged 1 retraction, 3 correx, after PubPeer comments

1st retraction for biologist who doctored 40+ images, received funding ban

JBC CoverThe Journal of Biological Chemistry has retracted a paper that was one of eight flagged in a recent investigation by the Office of Research Integrity (ORI). The investigation — which concluded that a biologist had falsified or fabricated more than 40 images — resulted in a five-year funding ban. 

In May, the ORI announced that John Pastorino, an erstwhile cell biologist at Rowan University in New Jersey, falsified and/or fabricated eight of his published papers (and one unpublished one). Nataly Shulga is a co-author on all eight papers. Six of those eight papers had already received expressions of concern (EOC).

The first retraction to result from the investigation is one of the two published papers that had not been tagged by an EOC. Here’s the retraction notice: Continue reading 1st retraction for biologist who doctored 40+ images, received funding ban

Genotyping mistake costs lab two papers and year of work

PNASResearchers are retracting two papers about molecular signalling in plants — including one from the Proceedings of the National Academy of Sciences (PNAS) — after discovering some inadvertent genotyping errors. But that was only after they used the problematic plants for an entire year without realizing they’d made a mistake.

In a pair of refreshingly transparent and detailed notices, the authors explain that the transgenic plants used in the papers included genotyping errors, which invalidated their findings. According to the notices, first author Man-Ho Oh generated the problematic transgenic plants, while corresponding author Steven C. Huber, based at University of Illinois, Urbana-Champaign (UIUC), took responsibility for omitting some critical oversight.

Huber told us that there were only two papers that used the transgenic plants in question, so no other retractions will be forthcoming.

Here’s the notice in PNAS for “Autophosphorylation of Tyr-610 in the receptor kinase BAK1 plays a role in brassinosteroid signaling and basal defense gene expression:”  Continue reading Genotyping mistake costs lab two papers and year of work

Researcher committed misconduct “recklessly,” says investigation

American Journal of Physiology Renal PhsyiologyA physiology journal has retracted a paper after an institutional investigation found that portions of the work had been falsified by the first author.

According to the notice issued by the American Journal of Physiology – Renal Physiology (AJP), the last author initiated the investigation at the University of Houston in Texas, which found the first author — Mousa Abkhezr — to be guilty of falsifying and duplicating images. 

We’ve obtained a copy of the investigation report, which concluded that Abkhezr committed misconduct “recklessly,” and the paper must be retracted. Although the report noted that Abkhezr argued that the problems stemmed from an honest error, the investigation committee ruled that data from the retracted paper cannot be included in his doctoral thesis.

The last author told us there is a separate ongoing “academic honesty enquiry” into Abkhezr’s dissertation. 

Here’s the retraction notice: Continue reading Researcher committed misconduct “recklessly,” says investigation

Plagiarism, plagiarism, plagiarism: Five recent cases

RW logoThere’s so much publishing news to report, we don’t always get to cover every retraction when it appears. To get the word out more quickly, sometimes we publish a group of papers pulled for similar reasons, such as duplications. Below, we present five recent cases of plagiarism, such as using text or figures that the authors didn’t originally write.

We’ve added the date of retraction where we could find it:
Continue reading Plagiarism, plagiarism, plagiarism: Five recent cases